Exchange: NYSE·Updated 02:29 PM EDT
News
all
press releases
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
Johnson & Johnson secures FDA clearance for MONARCH QUEST 3 software, boosting robotic bronchoscopy accuracy with AI. new 3D imaging tools.read more...
Benzinga
More News
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.
Zacks
Notable Tuesday Option Activity: JNJ, DAL, PWR
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Johnson & Johnson (Symbol: JNJ), where a total of 42,583 contracts have traded so far, representing approximately 4.3 million underlying shares. That amounts to about...
Nasdaq News: Markets
J&J's New Growth Powerhouses: Immunology and Neuroscience
J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.
Zacks
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
Zacks
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.
Zacks
This Dividend Aristocrat Posted Record Quarterly Results
Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving positive momentum post-earnings.
Zacks
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
Zacks
Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Zacks

Advertisement|Remove ads.